A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) (NCT06868628)

🧪 Interventions in This Study

• Foralumab Nasal (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Brigham and Women's Hospital — Boston, Massachusetts

📞 Contact the Study Coordinator

Phone: 857-307-542

Email: BWHMovementResearch@bwh.harvard.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple System Atrophy

• Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy — Rochester, Minnesota
• A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy — Los Angeles, California
• A Study of Lu AF82422 in Participants With Multiple System Atrophy — Fountain Valley, California
• GDNF Gene Therapy for Multiple System Atrophy — Irvine, California
• A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) — Scottsdale, Arizona
• Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic — Nashville, Tennessee

Explore by condition: All Multiple System Atrophy clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.